Business Wire

JDI

23.8.2024 09:01:29 CEST | Business Wire | Press release

Share
JDI Develops World's First Automotive Grade Dual Touch 2 Vision Display (2VD)

This press release is intended to redistribute the content that was already disclosed on August 2, 2024, for an international audience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240823676155/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

2 Vision Display (Graphic: Business Wire)

JDI has developed the world's first 2 Vision Display (2VD) technology that meets automotive grade image quality requirements while simultaneously displaying different image content based on viewing direction. As another world's first, JDI has incorporated Dual Touch into its new 2VD technology that identifies discrete touch operations from different users. JDI Dual Touch 2VD thus enables a single display to function as two separate touch-enabled displays.

2VD has existed as a concept for many years. Unfortunately, it has historically been unable to overcome image quality issues to achieve commercialization and product use.

With its new Dual Touch 2VD technology, JDI has deployed its world-leading LTPS and optics capabilities to generate the necessary breakthrough in image quality to allow for widespread use. As an automotive use case, JDI Dual Touch 2VD simultaneously provides a large-screen, rich-content information display to the driver to support safe driving and a large-screen, high-quality passenger display on a single display. Dual Touch 2VD also resolves interior design constraints caused by the increase in displays, while allowing the reduction of in-car display usage to support streamlined and sophisticated interior designs.

2VD has also historically lacked touch functionality, an important capability for many use cases. JDI Dual Touch 2VD uses JDI-developed custom ICs to identify whether touch operations originate from the driver or passenger (again, using an automotive use case example), allowing a single display to function as two separate touch-enabled displays.

JDI is currently in discussions with multiple global automobile OEMs to incorporate JDI Dual Touch 2VD into their next-generation vehicle interiors, with first shipment possible as early as 2025. In collaboration with these OEMs, JDI is working to create unprecedented levels of automobile safety and comfort.

Existing 2VD vs. New JDI Dual Touch 2VD

 

 Existing 2VD

New JDI

Dual Touch 2VD

Resolution

88 ppi

171 ppi

Brightness

350 nits

700 nits

Contrast

350 : 1

1000 : 1

NTSC Ratio

70%

85%

Touch Functionality

None

Dual Touch

Furthermore, JDI Dual Touch 2VD’s rich functionality goes beyond the automotive industry. It has a broad set of use cases in an extraordinarily rich variety of contexts, locations, and industries and in both horizontal and vertical 2VD modes. As examples, JDI Dual Touch 2VD can be deployed in large signage applications or to create display security and privacy enhancements through viewing angle control, or to support innovative gaming applications.

A sample vertical use case of JDI Dual Touch 2VD would be a large display at a transportation hub such as an airport or train station, in which the changing user viewing angle, depending on the distance between the display and the user, allows for the simultaneous provision of rich visuals, art or other creative content, general information, or advertising (at a distance) and departure/arrival information (up close).

JDI Dual Touch 2VD is a breakthrough display technology that has the potential to change the way displays are used – and shared – all over the world in fundamentally new ways. JDI looks forward to open innovation and collaboration with individuals, organizations, and creative communities globally to explore new use cases for JDI Dual Touch 2VD that enrich people’s daily lives. Please feel free to contact us at:
https://www.webcoms.jp/jdi/eng/form.php?pid=524

2 Vision Display presentation video
https://youtu.be/zBnz1GirUYE

[Provisional Translation Only]
This translation is provided solely for information purposes.
Should there be any discrepancies between this translation and the Japanese original, the latter shall prevail.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240823676155/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

Roboverse Reply Impresses at ELROB 2026 With Intelligent Robotic Systems for Critical Missions26.6.2026 10:00:00 CEST | Press release

Roboverse Reply, the Reply Group company specializing in robotics and automation, won the 1st Place in the “Reconnaissance” category and a special prize for “Best Team Effort” at the European Land Robot Trial (ELROB) 2026 in Thun, Switzerland. Teaming up with ELP, a specialist for technical equipment for defusing service, the company demonstrated outstanding performance alongside a field of international participants from June 15 to 19, proving that its autonomous solutions operate reliably under real-world conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626012237/en/ Roboverse Reply won 1st Place in the “Reconnaissance” category and a special prize for “Best Team Effort” at the European Land Robot Trial 2026, proving that its autonomous solutions operate reliably under real-world conditions. ELROB is Europe’s most demanding and established showcase for robotics and unmanned systems, where leading experts from

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye